Icenticaftor

DB21466InvestigationalSmall molecule

Icenticaftor is a small molecule drug. The usage of the INN stem '-caftor' in the name indicates that Icenticaftor is a Cystic fibrosis transmembrane regulator (CFTR) protein modulator, corrector, and... Icenticaftor is under investigation in clinical trial NCT04396366 (Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of QBW251 in Subjects With Bronchiectasis).

Mechanism: Pharmacologically active on Cystic fibrosis transmembrane conductance regulator
Curator reviewed
Formula / weight: C₁₂H₁₃F₆N₃O₃ · 361.244 g/mol (avg)
Code names: QBW-251

Resolves to

Compound

UNIIAMB0BO0WFHCAS1334546-77-8ChEMBLCHEMBL4650318ChEBI758218PubChem58442344

Structure

InChIKeyUSHQRIKZLHNPQR-JTQLQIEISA-NSMILESCOC1=C(C=C(N)C(=N1)C(=O)NC[C@](C)(O)C(F)(F)F)C(F)(F)F

Targets

P13569CFTR

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Icenticaftor, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account